Tim Kutzkey bought $590K of Surrozen (SRZN)
Executed Jan 15, disclosed Jan 21, 5 days later.
Over the 21 trading sessions from the disclosed entry session (Jan 20), the stock returned +25.5% (delay-adjusted); from the execution session (Jan 15), +22.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Tim Kutzkey (Director) filed 5 Form 4 reports in the trailing twelve months (5 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Surrozen, Inc. (SRZN). Across 5 priced purchase filings, the average 21-session return was +35.4% from execution and +20.0% from disclosure (delay-adjusted; derived). The largest single filing was $4.0M of SRZN (315,457 sh across 2 lots, as filed), executed Nov 13 2025.
Healthcare · Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→12,470 sh across 2 lots
Exec Jan 13
Filed Jan 15 · 4:11 PM ET SRZNPURCHASE Surrozen, Inc. $300K
15,100 sh across 2 lots
Exec Jan 6
Filed Jan 8 · 5:19 PM ET SRZNPURCHASE Surrozen, Inc. $604K
30,884 sh across 2 lots
Exec Dec 5 2025
Filed Dec 8 2025 · 5:09 PM ET SRZNPURCHASE Surrozen, Inc. $4.0M
315,457 sh across 2 lots
Exec Nov 13 2025
Filed Dec 2 2025 · 9:36 PM ET †